[(2-Pyridinesulfonylamino)methyl]-phosphonic acid | 318459-59-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: [(2-Pyridinesulfonylamino)methyl]-phosphonic acid
• 英文别名: (Pyridin-2-ylsulfonylamino)methylphosphonic acid
• CAS: 318459-59-5
• 化学式: C₆H₉N₂O₅PS
• 分子量: 252.188
• InChiKey: XIMGXQDIPMBKRH-UHFFFAOYSA-N

物化性质

• 沸点：
  548.5±60.0 °C(Predicted)
• 密度：
  1.654±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  125
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  吡啶-2-磺酰氯 生成 [(2-Pyridinesulfonylamino)methyl]-phosphonic acid
  参考文献：
  名称：

  Inhibitors of β-lactamase

  摘要：

  这项发明涉及细菌抗生素耐药性，特别是用于克服细菌抗生素耐药性的组合物和方法。该发明提供了新型β-内酰胺酶抑制剂，其在结构上与目前可用的天然产物和半合成β-内酰胺酶抑制剂无关，并且不需要β-内酰胺药效团。该发明还提供了用于抑制细菌生长的药物组合物和方法。

  公开号：

  US06884791B2

文献信息

• Sulfonamidomethyl phosphonate inhibitors of beta-lactamase
  申请人：MethylGene, Inc.

  公开号：US06472406B1

  公开（公告）日：2002-10-29

  The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel &bgr;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &bgr;-lactamase inhibitors presently available, and which do not require a &bgr;-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.

  这项发明涉及细菌抗生素耐药性，特别是用于克服细菌抗生素耐药性的组合物和方法。该发明提供了新型β-内酰胺酶抑制剂，其在结构上与目前可用的天然产物和半合成β-内酰胺酶抑制剂无关，并且不需要β-内酰胺药效团。该发明还提供了用于抑制细菌生长的药物组合物和方法。
• Novel inhibitors of beta-lactamase
  申请人：——

  公开号：US20040029836A1

  公开（公告）日：2004-02-12

  The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel &bgr;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &bgr;-lactamase inhibitors presently available, and which do not require a &bgr;-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.

  这项发明涉及细菌抗生素耐药性，特别是用于克服细菌抗生素耐药性的组合物和方法。该发明提供了新型β-内酰胺酶抑制剂，其在结构上与目前可用的天然产物和半合成β-内酰胺酶抑制剂无关，并且不需要β-内酰胺药效团。该发明还提供了用于抑制细菌生长的药物组合物和方法。
• Novel Inhibitors of beta-lactamase
  申请人：MethylGene, Inc.

  公开号：US20040082546A1

  公开（公告）日：2004-04-29

  The invention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel &bgr;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &bgr;-lactamase inhibitors presently available, and which do not require a &bgr;-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.

  这项发明涉及细菌抗生素耐药性，特别是用于克服细菌抗生素耐药性的组合物和方法。该发明提供了新型β-内酰胺酶抑制剂，其在结构上与目前可用的天然产物和半合成β-内酰胺酶抑制剂无关，并且不需要β-内酰胺药效团。该发明还提供了用于抑制细菌生长的药物组合物和方法。
• [EN] SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF beta -LACTAMASE<br/>[FR] INHIBITEURS SULFONAMIDOMETHYL-PHOSPHONATE DE LA beta -LACTAMASE
  申请人：METHYLGENE INC

  公开号：WO2001002411A1

  公开（公告）日：2001-01-11

  The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel β-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic β-lactamase inhibitors presently available, and which do not require a β-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.

  本发明涉及细菌抗生素抗性，特别是涉及克服细菌抗生素抗性的组合物和方法。本发明提供了新型β-内酰胺酶抑制剂，其与目前已有的天然产物和半合成β-内酰胺酶抑制剂在结构上没有关联，并且不需要β-内酰胺药效团。本发明还提供了用于抑制细菌生长的药物组合物和方法。
• Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase
  申请人：——

  公开号：US20040059115A1

  公开（公告）日：2004-03-25

  The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel &bgr;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &bgr;-lactamase inhibitors presently available, and which do not require a &bgr;-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.

  本发明涉及细菌抗生素耐药性，特别是涉及克服细菌抗生素耐药性的组合物和方法。本发明提供了新型β-内酰胺酶抑制剂，其与目前已有的天然产物和半合成β-内酰胺酶抑制剂结构上无关，且不需要β-内酰胺药效团。本发明还提供了用于抑制细菌生长的药物组合物和方法。